FerumoxytolNausea following off-label use: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2017年 / 1650卷 / 1期

关键词：

D O I：

10.1007/s40278-017-29674-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：142 / 142

相关论文

共 50 条

[31] Cladribine/vemurafenibLack of efficacy following off-label use: 2 case reports
[J]. Reactions Weekly, 2021, 1858 (1) : 118 - 118
[32] RituximabCystoid macular oedema following off-label use: 2 case reports
[J]. Reactions Weekly, 2021, 1869 (1) : 320 - 320
[33] Multiple drugsLack of efficacy following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1907 (1) : 333 - 333
[34] Azithromycin/hydroxychloroquineQTc prolongation following off-label use: 2 case reports
[J]. Reactions Weekly, 2021, 1842 (1) : 83 - 83
[35] FavipiravirHyperuricaemia and lack of efficacy following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1903 (1) : 182 - 182
[36] SpironolactoneHyperkalaemia following off-label use: 3 case reports
[J]. Reactions Weekly, 2023, 1949 (1) : 385 - 385
[37] ImiquimodLymphoedema following off-label use: 3 case reports
[J]. Reactions Weekly, 2018, 1711 (1) : 146 - 146
[38] Favipiravir/hydroxychloroquine/methylprednisoloneNephrotoxicity following an off-label use: 2 case reports
[J]. Reactions Weekly, 2021, 1871 (1) : 172 - 172
[39] DexamethasoneReactivation of Strongyloides stercoralis following off-label use: 2 case reports
[J]. Reactions Weekly, 2021, 1866 (1) : 146 - 146
[40] Lopinavir/ritonavirLack of efficacy following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1903 (1) : 225 - 225

← 1 2 3 4 5 →